Software Validation Observations in FDA Warning Letters and Consent Decrees: Patterns, Root Causes, and Remediation Expectations

Software validation observations continue to appear in FDA warning letters, inspection observations, and consent decrees across a wide range of regulated industries. While the specific technologies, systems, and business processes may differ, recurring patterns often emerge involving validation scope, change management, risk assessment, user requirements, testing rationale, electronic records, data integrity controls, and ongoing system oversight. These observations frequently involve expectations associated with 21 CFR Part 11, 21 CFR Parts 210 and 211, and software validation principles described within FDA guidance documents. In many cases, the underlying issue extends beyond a missing document or incomplete protocol and reflects broader weaknesses in how organizations make and defend software validation decisions.

This session examines software validation observations through the lens of regulatory enforcement actions and remediation efforts. The discussion will focus on recurring compliance patterns, the organizational decisions that contributed to those outcomes, and the corrective actions regulators ultimately expected organizations to implement. Practical examples will be used to explore how validation weaknesses develop, how they are identified during inspections, and how organizations can strengthen validation programs before similar issues attract regulatory attention.

| WHY YOU SHOULD ATTEND

FDA warning letters and consent decrees often involve software systems that were already in routine use. The systems were supporting manufacturing, quality, laboratory, clinical, or business operations. Records were being generated. Data was being reviewed. Products were being released. Yet during inspections, regulators concluded that the validation evidence, risk controls, change management practices, or system oversight activities were insufficient to support continued reliance on those systems.

Organizations subject to Part 11 and GMP requirements often discover that enforcement actions focus less on the existence of validation documentation and more on whether validation decisions remained scientifically justified, risk-based, and sustainable over time. Looking across warning letters and consent decrees reveals recurring patterns in how validation decisions break down, how weaknesses are discovered, and what FDA ultimately expects organizations to do when significant deficiencies are identified. This session examines those patterns and the practical lessons they offer for modern software validation programs.

| AREAS COVERED

• Recurring Software Validation Deficiencies Found in FDA Warning Letters and Consent Decrees
• Validation Decisions That Commonly Create Long-Term Compliance Exposure
• Part 11, Data Integrity, and Electronic Records Issues Behind Major Enforcement Actions
• Risk Assessment Weaknesses Frequently Cited During FDA Inspections
• Change Management Practices Behind Significant Regulatory Observations
• FDA Remediation Expectations Following Major Validation Findings
• Evidence Inspectors Expect When Software Validation Decisions Are Challenged
• Lessons Learned from Real Enforcement Actions Under GMP and Part 11 Requirements

| WHO SHOULD ATTEND

• Validation Professionals
• Computer System Validation (CSV) Teams
• Quality Assurance (QA) Departments
• Quality Systems Personnel
• Regulatory Affairs Departments
• IT and Business System Owners
• Compliance and Audit Professionals
• Pharmaceutical, Biotechnology, and Medical Device Manufacturers

Course Director: Meredith Crabtree

Meredith Crabtree has over 30 years’ experience in regulated industries, ranging from Blood, Plasma, Tissue, Laboratory, Pharma, Medical Device, Cosmetics, Supplements, and Animal Health. This includes manufacturing, packaging, labelling and distribution operations. Meredith is the owner of MLKC Consulting is s a Quality Consultant specializing in product label reviews, 3rd party inspections, Consent Decree and Recall support. She also performs regulatory assessments and Quality trainings.